Expert peer review No.2 on application for anti parkinsonism medicines
|
|
- Clement Francis
- 5 years ago
- Views:
Transcription
1 Expert peer review No.2 on application for anti parkinsonism medicines 1. Assessment of efficacy a. Have all relevant studies on efficacy been included Yes No (if no, please provide reference and information) Attachment 1 5 part 1 2 b. Summarize the data on efficacy, in comparison to what is listed in EML where applicable (limit to 2 to 3 sentences). (1) Levodopa/carbidopa (L/C): L/C (100/20) is more effective than L/C (100/10) in treatment of Parkinson s disease (PD) [1]. L/C 300mg:75mg per day is effective and safe for PD [2]. (2) Pramipexole: A significant improvement occurred in the total Unified Parkinson s Disease Scale (UPDRS) score with pramipexole monotherapy compared with placebo and bromocriptine [3 4]. When used as adjunct therapy in parkinson s disease (PD), it is also significant better than levodopa [5]. Pramipexole treatment of depression symptoms achieved a significant advantage in Hamilton depression scale (HAM D) compared with placebo, but had no difference with other anti depression drugs [6]. (3) Selegiline: Compared with placebo, selegiline do not appear to delay disease progression in terms of improved survival, but may improve patient s compliance and symptoms [7]. (4) Trihexyphenidyl: Early study indicated trihexyphenidyl could improve neural function [8]. Trihexyphenidyl was equally effective as biperiden (WHO EML medicine) [9]. (5) Amantadine: There is insufficient evidence to support the use of amantadine for early Parkinson s disease (PD) [10]. The results from our study suggested that amantadine can be used as an antidyskinesia agent [11 12]. c. Please provide any additional relevant information with reference See references and attachment 1 5 part Assessment of safety a. Have all relevant studies on safety been included Yes No (if no, please provide reference and information) Attachment 1 5 part 1 2 b. Summarize the data on safety, in comparison to what is listed in EML where applicable (limit to 2 to 3 sentences) (1) L/C: L/C mainly causes ADRs in digestive system (nausea 26%, constipation 8%, dyspepsia 6%), motor system (dystonia 16%, freezing of gait 7%, falls 5%), nervous system (depression 8%, dizziness 6%, somnolence 6%, insomnia 5%, tremor 5%); as well as wearing off (18%) [2]. (2) Pramipexole: The majority of adverse events associated with pramixezole are in nervous system, such as insomnia, illusion, dizziness, movement disorders, etc. Besides that, nausea, constipation, peripheral oedema and postural hypotension are also common adverse events. Most adverse events are mild, however cases of heart failure were reported. (3) Selegiline: The most frequently reported adverse events including nervous system (such as vertigo, hallucinations, depression, dizziness, anxiety) [13], circulating system (such as postural hypotension, palpitation), digestive system (such as nausea, dry mouth, constipation) [14], endocrine system ( such as sweat). No serious adverse events were reported based on our included studies [15]. (4) Trihexyphenidyl: Trihexyphenidyl was reported resulting in mental symptoms (7 cases), myasthenia gravis (1 case), toxicosis (4 cases), and drug dependence (2 cases) (5) Amantadine: Most adverse events are mild, the most frequently reported adverse events included nervous system (53.23%), digestive system(35.48%), others system(total: 18.99%) [16] c. Please provide any additional relevant information with reference See references and attachment 1 5 part Assessment of cost and availability a. Have all relevant data on cost provided Yes No (if no, please provide reference and information) b. Summarize the data on cost and cost effectiveness, in comparison to what is listed in EML where applicable (limit to 2 to 3 sentences) 1
2 (1) L/C: In China, controlled release L/C (200mg:50mg) 30= 68.4=$ Therefore yearly cost (100mg:25mg three times daily) is approximately $ (2) Pramipexole: In China, pramixezole 0.25mg 30= Therefore yearly cost (0.5mg three times daily) is approximately $ (3) Selegiline: In China, selegiline hydrochloride tablets: 5mg 10= 34.3= $ Therefore 1 year treatment of 10mgs daily is $ (4) Trihexyphenidyl: In China, trihexyphenidyl 2mg 100= 3.7=$0.59. Therefore yearly cost (2mg three times daily) is approximately $6.50. (5) Amantadine: In china, amantadine hydrochloride tablets: 100mg 100 = $ Therefore yearly cost (100mg twice daily) is approximately $8.17. c. Please provide any additional relevant information with reference None d. Is the product available in several low and middle income countries? Trihexyphenidyl was included by National Essential Medicines List (NEML) (2009 edition) and National Essential Medical Insurance Medicine List (NEMIML) of China (2009 edition, 100% reimbursed). Amantadine was included by NEML and NEMIML(partially reimbursed). L/C was included by NEMIML(partially reimbursed). Pramipexole and selegiline were available in China, but not included by NEML nor NEMIML. 4. Assessment of public health need a. Please provide the public health need for this product (1 2 sentences) Table 1 The burden of inpatients with PD (data from China Health Statistics Yearbook 2011) Total patients PD Cure Improvement Unhealed Death Average cost ( ) 5y 5~14y 15~44y 45~59y 60y PD (0.1) b. Do guidelines (especially WHO guidelines) recommend this product? If yes, which ones? List 1 or 2 international preferable Guideline recommended as following: L/C [17 21] and pramipexole [17 20] were recommended as first choice option for early PD, and pramipexole could be used as anti depression therapy for PD patients. Selegiline was recommended as a symptomatic treatment for PD [17 19,21]. Trihexyphenidyl only use in mild parkinsonian symptoms in people with no cognitive dysfunction [17], and in PD patients with tremor [18,20]. Amantadine was used as an antidyskinesia agent [17 20]. 5. Are there special requirements for use or training needed for safe/effective use? If yes, please provide details in 1 2 sentences Yes. L/C appropriate to adjust L/C dosage to reduce motor complications. L/C and Selegiline are contraindicated in pregnancy. Pramipexole and Trihexyphenidyl should be titrated to a clinically efficacious dose. Amantadine should not be taken later than mid afternoon due to its ADR of insomnia, and patients with history of seizures and psychiatric symptoms should be monitored. 6. Is the proposed product registered by a stringent regulatory authority? Yes No 7. Any other comments Trihexyphenidyl is more available and cheaper than biperiden (WHO EML medicine). 8. What is your recommendation to the committee (please provide the rationale) (1) We recommend L/C (4:1) replace L/C (10:1) in WHO EML, due to: L/C (4:1) was proved to be effective and safe for PD by high quality RCT. 2
3 L/C (100/20) is more effective than L/C (100/10) for PD by another RCT. (2) We recommend pramixezole be listed in WHO EML only if cost is not considered, due to: Pramixezole is efficient in treating PD patients by improving the total UPDRS scores and depression symptom in PD patients by improving the HAM D scores. The adverse events of pramixezole included nervous system, circulating system, digestive system and endocrine system. The cost of pramixezole ($ 2514 per year) is much higher than the other four anti parkinsons drugs (selegiline $401.12, levodopa $200, amantadine $8.17, benzhexol $6.4). (3) We recommend selegiline be listed in WHO EML only if cost is not considered, due to: Compared with placebo, selegiline do not appear to delay disease progression in terms of improved survival, but may improve patient s compliance and symptoms. The adverse events of selegiline included nervous system, circulating system, digestive system and endocrine system based on our included studies. The cost of selegiline ($401.12per year) is higher than levodopa ($200.00per year), benzhexol ($6.40per year) and amantadine ($8.17per year). (4) We do not recommend trihexyphenidyl be listed in WHO EML. Unless WHO will keep anticholinergics medicine in EML, then we recommend trihexyphenidyl replace biperiden, since: There are insufficient clinical evidence on the efficacy and safety of trihexyphenidyl for PD. Trihexyphenidyl is more available and cheaper than biperiden. (5) We do not recommend amantadine list in WHO EML, due to: Guidelines recommend amantadine used as an antidyskinesia agent (C) Only those with dyskinesia will be eligible for amantadine, and the patients (especially elderly and those with cognitive decline) should be warned about potential onset, or increase of, visual hallucinations. Amantadine might be used for early PD but should not be a drug of first choice (D). References: 1. WW Tourtellotte, K Syndulko, AR Potvin, et al. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease. Arch Neurol, 1980, 37(11): S Fahn, D Oakes, I Shoulson, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med, 2004, 351(24): Möller JC, Oertel WH, Köster J, et al. Long term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord May;20(5): Clarke CE, Patel S, Ives N, et al. Should PD treatment be started immediately on diagnosis or delayed until functional disability develops? Meta analysis of delayed start design trials. Mov Disord Jun;26(7): Carl E Clarke, Julie Speller, J A Clarke, et al. Pramipexole for levodopa induced complications in Parkinson's disease. Cochrane Database of Systematic Reviews.2000(2):CD updated 6. Leentjens AF, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta analysis of placebo controlled studies. Clin Ther Jan; 31(1): Turnbull K, Caslake R, Macleod A, et al. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD DOI: / CD pub2. 8. R Katzenschlager, C Sampaio, J Costa, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev, 2003(2): CD RV Magnus. A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug induced Parkinsonism. J Int Med Res, 1980, 8(5):
4 10. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database of Systematic Reviews. 2003(1):CD Crosby NJ, Deane KHO, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database of Systematic Reviews. 2003(2):CD Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to Movement Disorders. May 2005;20(5): Myllylä VV, Sotaniemi KA, Hakulinen P, et al. Selegiline as the primary treatment of Parkinson's disease a long term double blind study.acta Neurol Scand. 1997,95(4): Pålhagen S, Heinonen EH, Hägglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.Neurology. 1998,51(2): Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa treated Parkinson's disease: a randomized placebo controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.ann Neurol. 2002,51(5): Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in parkinson's disease: A randomized controlled trial. PLoS ONE. 2010;5(12). 17. Parkinson's Disease: National clinical guideline for diagnosis and management in primary and secondary care2006, London: Royal College of Physicians of London. 18. 中国帕金森病治疗指南 ( 第二版 )[J]. 中华神经科杂志, 2009, 42(5): D Grimes, J Gordon, B Snelgrove, et al. Canadian Guidelines on Parkinson's Disease. Can J Neurol Sci, 2012, 39(4 Suppl 4): S J Carr, B Kies, and J Fine. Guideline for the treatment of Parkinson's disease. S Afr Med J, 2009, 99(10): 755 6, DG Grosset, GJ Macphee, and M Nairn. Diagnosis and pharmacological management of Parkinson's disease: summary of SIGN guidelines. BMJ, 2010, 340: b
5 Attachment 1: Comparison of Application and Evaluation for anti-parkinsonism medicines: Levodopa/carbidopa(L/C) Items Data of Application Data of Evaluation 1.Included Studies No. of IS No. of IP Additional Total No. of IS No. of IP No. of IS No. of IP Efficacy SR/meta analysis RCT CCT Case series Case report Safety Applicability Economical Evaluation Outcomes of Evaluation Efficacy Mortality 20% (4/20) Idem Idem Symptom control UPDRS, PLB vs L/C(150vs300vs600) 7.8/1.9/1.9/1.4 n=361 Safety# Nervous system Depression(0.08),Dizziness(0.06), Somnolence(0.06),Insomnia(0.05), Tremor(0.05) Motor system Dystonia(0.16),Freezing of gait(0.07),falls(0.05),myalgia(0.03),dyskinesia(0.02) Digestive system Nausea(0.26),Constipation(0.08), Dyspepsia(0.06),Diarrhea(0.03) Symptom, L/C(100:20 vs 100:10) 100:20 > 100:10 One upper limb tremor exacerbation case report One 'on-off' exacerbation case report - Idem Respiratory system Upper respiratory infection(0.11),sinusitis(0.05) - Idem UPDRS,7.8/1.9/1.9/1.4 Symptom,100:20 > 100:10 Idem + 1 upper limb tremor exacerbation case Idem + 1 'on-off' exacerbation case Circulatory system Hypertension(0.02),Coronary artery disorder*(0.02) One hypertensive crisis case report Idem + 1 hypertensive crisis case* Urinary system Urinary tract infection(0.01) - Idem Reproductive system Endocrine system Others Wearing off(0.18),back pain(0.06), Headache(0.06),Chest pain*(0.05) Applicability For early PD For early PD One burning mouth syndrome and 1 skin rash case report Idem + 1 burning mouth syndrome + 1 skin rash case Economical Evaluation 700 USD per year 200 USD per year in China, controlled-release L/C may be more cost-effective in PD patients with motor fluctuations than standard L/C. 3.Quality of Evidence A A 5
6 4.Recommendation First-choice option for early PD. First-choice option for early PD. #Safety data mainly based on L/C(300mg:70mg/day) from Fahn 2004 study. Attachment 2: Comparison of Application and Evaluation for anti-parkinsonism medicines: Pramixezole Items Data of Application Data of Evaluation 1.Included Studies No. of IS No. of IP Additional Total No. of IS No. of IP No. of IS No. of IP SR/meta analysis RCT Efficacy CCT Case series Case report Safety Applicability Economical Evaluation Outcomes of Evaluation Efficacy Mortality Symptom control UPDRS total score,: PPX vs PLB 4.4 CI95%( )P< Safety Nervous system Hallucinations, Confusion 6 UPDRS total score: PPX vs PLB[MD=-13.2,95%CI(-15.53,-10.51),P< ] PPX vs BR[OR=2.66,95%CI(1.41,5.02),P=0.003] PPX+L-dopa vs L-dopa[MD=-9.35,95%CI(-13.83,-1.23),P<0.0001] HAM-D score: PPX vs other drugs [MD=1.08,95%CI(0.75,2.9),P< ] Dizziness15.5%, Dyskinesia12.9%, Insomnia8.2%, Somnolence8.6%, Hallucination6.6%, Confusion3.0%, headache6.5%, Dreams anomaly3.5% case report:impulse Control Disorders,5 Sudden sleep attacks,psychotic disorder Motor system Dyskinesia case report:8 camptocormia,3 antecollis,dropped head syndrome Digestive system Nausea Nausea17.2%,Constipation5.5% Respiratory system - - Circulatory system Postural hypotension Postural hypotension, heart failure* Urinary system - - Reproductive system - - Endocrine system - case report:2 SIADH,significant weight increase,dysaphrodisia Others Peripheral oedema Peripheral oedema Applicability For early PD For early PD Economical Evaluation 0.7mg tid, 786/y in UK 0.5mg tid, 15696/y= $2514/y in China 3.Quality of Evidence A A
7 4.Recommendation First-choice option for early PD First-choice option for early PD. Depression in PD patients. Attachment 3: Comparison of Application and Evaluation for anti-parkinsonism medicines: Selegiline Items Data of Application Data of Evaluation 1.Included Studies No. of IS No. of IP Additional Total No. of IS No. of IP No. of IS No. of IP SR/meta analysis RCT Efficacy CCT Case series Case report Safety Applicability Economical Evaluation Outcomes of Evaluation Efficacy Mortality selegiline(84/615) vs placebo(82/611) selegiline(210/475) + other therapy vs other therapy(178/451) selegiline vs placebo: [OR=1.03,95%CI(0.73,1.44), P=0.87] selegiline + other therapy vs other therapy:[or=1.25,95%ci(0.91, 1.71),P=0.16] selegiline(83/566) vs placebo(77/551) selegiline(218/582) + other therapy vs other therapy(182/554) selegiline vs placebo: [RR=1.06,95%CI(0.80,1.41),P=0.70] selegiline + other therapy vs other therapy: [RR=1.10,95%CI(0.97,1.24),P=0.14] Symptom control _ selegiline vs placebo: [MD=-4.57,95%CI(-5.70,-3.44), P< ] selegiline + other therapy vs other therapy:[md=-4.12,95%ci(-6.58, -1.65),P=0.0011] _ Safety nervous system (hallucinations) (vertigo, hallucinations, depression, dizziness, anxiety) motor system _ digestive system _ (nausea, dry mouth, constipation) 12.04% respiratory system _ circulatory system (postural hypotension) (postural hypotension, palpitation) 4.28% urinary system _ reproductive system _ endocrine system _ (sweat) 1.27% others _ Applicability initial or add-on treatment for PD symptomatic treatment for PD. 7 selegiline vs placebo: [SMD=-0.46,95%CI(-0.74,-0.18), P=0.001] selegiline + other therapy vs other therapy:[smd=-2.72,95%ci(-7.29, 1.85),P=0.24] 17.27%
8 Economical Evaluation USD per year USD per year in China 3.Quality of Evidence A A 4.Recommendation Selegiline may be used both as initial and add-on treatment for people with PD. Attachment 4: Comparison of Application and Evaluation for anti-parkinsonism medicines: Trihexyphenidyl Selegiline may be used as a symptomatic treatment for people with PD, but the cost of it is higher than levodopa($200.00), benzhexol ($6.40) and amantadine ($8.17). We do not recommend selegiline included to the WHO EML. Items Data of Application Data of Evaluation 1.Included Studies No. of IS No. of IP Additional Total No. of IS No. of IP No. of IS No. of IP Efficacy SR/meta analysis RCT CCT Case series Case report Safety Applicability Economical Evaluation Outcomes of Evaluation Efficacy Mortality - - Symptom control - Neural function improved Idem Safety Nervous system - Seven mental anomaly cases report Idem Motor system - One myasthenia gravis case report Idem Digestive system Respiratory system Circulatory system Urinary system Reproductive system Endocrine system Others - Four toxicosis, two drug dependence, one blindness*, one dysphonia plicae ventricularis, one fever, one spider angiomas cases report Idem Applicability Replace biperiden for PD Young PD patients with tremor Economical Evaluation 263 USD per year 6.5 USD per year in China 3.Quality of Evidence D C 8
9 4.Recommendation Replace biperiden for PD. Not recommended as first-choice option for PD. Attachment 5: Comparison of Application and Evaluation for anti-parkinsonism medicines: Amantadine Items Data of Application Data of Evaluation 1.Included Studies No. of IS No. of IP Additional Total No. of IS No. of IP No. of IS No. of IP Efficacy SR/meta analysis RCT cross-over study CCT Case series Case report Safety Applicability Economical Evaluation Outcomes of Evaluation Efficacy Mortality Symptom control amantadine reduces dyskinesia in Parkinson s disease amantadine is effective for dyskinesias in Parkinson s disease Idem Safety Nervous system visual hallucinations,insomnia 53.23%,N=14 eg:visual hallucination,tircdncss,giddiness,headache, insomnia,depression Idem Motor system %,N=4 eg:myoclonus Idem Digestive system % eg:dryness of mouth,constipation Idem Respiratory system Circulatory system - N=3,eg:Circulatory disorders Idem Urinary system %,eg:Frequency Micturition Idem Reproductive system Endocrine system Others % N=14 eg: livedo reticularis,corneal edema Idem 9
10 Applicability for dyskinesia in PD for dyskinesia in PD Economical Evaluation USD per year 8.17 USD per year 3.Quality of Evidence C C 4.Recommendation for dyskinesia in PD for dyskinesia in PD Abbreviations:SR:systematic review, RCT:randomized controlled trial, CCT:controlled clinical trial, IS:included studies, IP:included patients, PLB:placebo, PD:Parkinson's disease, PPX:pramixezole, BR:bromocriptine, :reported, *:serious adverse reaction, :no reports found 10
What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease
FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationThe Use of Amantadine HCL in Clinical Practice: A Study of Old and New Indications
The Use of Amantadine HCL in Clinical Practice: A Study of Old and New Indications Carlos Singer, MD* Spiridon Papapetropoulos, MD, PhD* Gadith Uzcategui, BA Lydia Vela, MD * Department of Neurology, University
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationEarly Pharmacologic Treatment in Parkinson s Disease
n report n Early Pharmacologic Treatment in Parkinson s Disease Robert A. Hauser, MD, MBA Abstract Early treatment of Parkinson s disease (PD) affords an opportunity to forestall clinical progression.
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationSponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia
Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS INFUSION THERAPIES IN PARKINSON S DISEASE Apomorphine, T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR FLUCTUATIONS
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationCh. 4: Movement Disorders
Ch. 4: Movement Disorders Hiral Shah, MD Parkinson s Disease and DOPA Cotzias GC, Van Woert MH, and Schiffer, LM. Aromatic Amino Acids and Modification of Parkinsonism. N Engl J Med 1967; 276: 374-379.
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationReport on New Patented Drugs Azilect
Report on New Patented Drugs Azilect Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationEvidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease: 2001 to 2004
Movement Disorders Vol. 20, No. 5, 2005, pp. 523 539 2005 Movement Disorder Society Research Review Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease:
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationRotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research
Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Synthetic DRUG PROFILE Introduction Parkinson s disease (PD) is a neurodegenerative disorder
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationSECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS
SECTION 9 : MANAGEMENT OF MOVEMENT DISORDERS AND EXTRAPYRAMIDAL SIDE EFFECTS Formulary and Prescribing Guidelines 9.1 Introduction Movement disorders and extrapyramidal side effects can manifest in the
More informationPDL Class: Parkinson s Drugs
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review: September 2013 Date of Last Review:
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and futher notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and futher notice) This drug has been reviewed because it is a product that may be prescribed in primary care.
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationCONTINUOUS THERAPY BECAUSE LIFE GOESON
CONTINUOUS THERAPY BECAUSE LIFE GOESON Investigating the effectiveness and safety of ND0612, an investigational medicine for patients with advanced Parkinson s Disease New medication limited by Federal
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationFOR PARKINSON S DISEASE XADAGO NEXT?
FOR PARKINSON S DISEASE XADAGO can increase your daily on time without troublesome dyskinesia 1 Please see the complete Important Safety Information on pages 12-13 and the accompanying full Prescribing
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationSIFROL Composition Properties Indication
SIFROL Boehringer Composition 1 tablet contains: 0.125, 0.25 or 1.0 mg, (S)-2- amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole dihydrochloride monohydrate equivalent to 0.088, 0.18 or 0.7 mg pramipexole
More informationRasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature
Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationParkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC
Parkinson s Disease in 60 minutes Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC S Plan of attack S What causes Parkinson s disease brief S Symptoms/Diagnostic
More informationPatients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment
For the attention of accredited medical writers only Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment Data presented at the 7
More informationThe art of treating Parkinson disease in the older patient
CLINICAL PRACTICE: Therapeutic review The art of treating Parkinson disease in the older patient Daniel Kam Yin Chan, MD, MHA, MBBS, FRACP, FHKCP, AFCHSE, is Associate Professor, University of New South
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationChapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis
Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral
More informationPost hoc analysis from RECOVER study examined effects of Neupro (rotigotine) on surrogate markers of mood and anhedonia in Parkinson s disease
For the attention of Accredited Medical Writers Only Post hoc analysis from RECOVER study examined effects of Neupro (rotigotine) on surrogate markers of mood and anhedonia in Parkinson s disease Brussels
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationKeywords: deep brain stimulation; subthalamic nucleus, subjective visual vertical, adverse reaction
Re: Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation Norbert Kovacs 1*, Jozsef Janszky 1, Ferenc
More informationWith Time, The Pathology of PD Spreads Throughout the Brain
With Time, The Pathology of PD Spreads Throughout the Brain Braak s staging of Parkinson s disease pathology dm co sn mc hc fc 1 Hubert H. Fernandez, MD, FAAN Professor of Medicine (Neurology) Cleveland
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationNeupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease
For the attention of accredited medical writers only Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease Detailed
More informationRotigotine provided sustained efficacy and tolerability in long term studies of early and late stage idiopathic Parkinson s disease
New data presented at the American Academy of Neurology meeting showed that Neupro (rotigotine transdermal system) improved both motor and non-motor symptoms of Parkinson s disease Analysis of RECOVER
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDrugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
More informationAbbreviated Class Update: Parkinson s Drugs. Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. MAO- B** Inhibitors
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Abbreviated Class Update: Parkinson s Drugs Month/Year of Review: November 2013 End of literature
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPRODUCT INFORMATION. AKINETON (biperiden hydrochloride 2 mg tablets)
PRODUCT INFORMATION AKINETON (biperiden hydrochloride 2 mg tablets) NAME OF THE MEDICINE Non-proprietary name: biperiden hydrochloride Structural formula (biperiden): Chemical name (biperiden): α-5-norbornen-2-yl-α-phenyl-1-piperidine
More informationHM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationOptimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
EXPERT OPINION Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective David J Brooks Division of Neuroscience, Faculty
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationRECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease
For the attention of Accredited Medical Writers Only RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease Post hoc analyses of RECOVER study suggested
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationSafinamide: un farmaco innovativo con un duplice meccanismo d azione
Safinamide: un farmaco innovativo con un duplice meccanismo d azione AINAT Sardegna Cagliari, 26 novembre 2016 Carlo Cattaneo Corporate Medical Advisor CNS & Rare Diseases Reichmann H. et al., European
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationKEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)?
KEY SUMMARY 1. Mirapexin /Sifrol (pramipexole*) is a selective non-ergot dopamine agonist approved as immediate release since 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's
More information(safinamide) tablets
FOR PARKINSON S DISEASE (PD) GET TO KNOW XADAGO can increase your daily on time without troublesome dyskinesia (uncontrolled movement) Please see the complete on pages 14-15 and For Parkinson s disease
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationDisease Progress. Clinical Pharmacology = Disease Progress + Drug Action. Outline. Parkinson s Disease. Interpretation of ELLDOPA
1 Disease Progress Parkinson s Disease Interpretation of ELLDOPA Nick Holford Dept Pharmacology and Clinical Pharmacology University of Auckland 2 Clinical Pharmacology = Disease Progress + Drug Action
More informationAUSTRALIAN PI SIMIPEX (pramipexole dihydrochloride monohydrate)
AUSTRALIAN PI SIMIPEX (pramipexole dihydrochloride monohydrate) 1 NAME OF THE MEDICINE Pramipexole dihydrochloride monohydrate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pramipexole dihydrochloride monohydrate
More informationPRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate)
PRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate) NAME OF THE MEDICINE Pramipexole hydrochloride monohydrate. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationTreatment of Influenza. Dr. YU Wai Cho
Treatment of Influenza Dr. YU Wai Cho Symptomatic Treatment Analgesics/ Antipyretics (avoid aspirin) Adequate fluids Rest Specific Drug Treatment Synthetic amines Amantadine Rimantadine Neuraminidase inhibitors
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor Novartis. Generic Drug Name AFQ056. Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID)
Sponsor Novartis Generic Drug Name AFQ056 Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Investigational Protocol Number CAFQ056A2223 Title 13-week,
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationAUSTRALIAN PRODUCT INFORMATION APO-PRAMIPEXOLE ER (PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE ) MODIFIED RELEASE TABLET
AUSTRALIAN PRODUCT INFORMATION APO-PRAMIPEXOLE ER (PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE ) MODIFIED RELEASE TABLET 1 NAME OF THE MEDICINE Pramipexole Dihydrochloride Monohydrate 2 AND 3 QUALITATIVE AND
More information